» Articles » PMID: 37280662

Hospitalization for Bronchiolitis in Children Aged ≤ 1year, Southern Italy, Year 2021: Need for New Preventive Strategies?

Abstract

Background: Bronchiolitis is a major cause of hospitalization in infants, particularly in the first six months of life, with approximately 60-80% of admissions due to respiratory syncytial virus (RSV) infection. Currently, no prophylactic options are available for healthy infants. The present study aimed at describing the demographic, clinical, and epidemiological characteristics of infants hospitalized for bronchiolitis in the Apulia region of Italy in 2021.

Methods: From January to December 2021, data on children aged 0-12 months admitted for bronchiolitis in nine neonatal or pediatric units covering 61% of pediatric beds of hospitals in the Apulia region of Italy were analyzed. Demographic data, comorbidities, need for oxygen support, length of hospital stay, palivizumab administration, and outcomes were collected. For the purpose of the analysis, patients were divided into those aged 0-3 months and > 3 months. A multivariate logistic regression model was used to explore associations between the need for oxygen support and sex, age, comorbidities, history of prematurity, length of hospital stay, and palivizumab administration.

Results: This study included 349 children aged 0-12 months admitted for bronchiolitis, with a peak of hospitalization in November (7.4 cases/1,000 children). Of these patients, 70.5% were RSV positive, 80.2% were aged 0-3 months, and 73.1% required oxygen support. Moreover, 34.9% required observation in the sub-intensive care unit, and 12.9% in the intensive care unit. Of the infants who required intensive care, 96.9% were aged 0-3 months and 78.8% were born at term. Three patients required mechanical ventilation and one, who required Extra Corporeal Membrane Oxygenation, died. Children aged 0-3 months were more likely to show dyspnea, need oxygen support, and have a longer hospital stay.

Conclusions: The present study showed that almost all of the children who required intensive care support were aged ≤ 3 months and most were born at term. Therefore, this age group remains the highest risk group for severe bronchiolitis. Preventive measures such as single-dose monoclonal antibody immunoprophylaxis, and maternal and childhood vaccination against RSV, may reduce the high public health burden of bronchiolitis.

Citing Articles

Changes in Respiratory Viruses' Activity in Children During the COVID-19 Pandemic: A Systematic Review.

Maglione M, Tipo V, Barbieri E, Ragucci R, Ciccarelli A, Esposito C J Clin Med. 2025; 14(4).

PMID: 40004915 PMC: 11856189. DOI: 10.3390/jcm14041387.


Hospitalizations for bronchiolitis among infants before and after the SARS-CoV-2 pandemic: an area-based study of the Emilia-Romagna Region, Italy.

Ballardini E, Manfrini M, Fattori S, Pellacani E, Cosic B, Gargano G Ital J Pediatr. 2025; 51(1):34.

PMID: 39920754 PMC: 11806670. DOI: 10.1186/s13052-025-01871-6.


Advances in pediatrics in 2023: choices in allergy, analgesia, cardiology, endocrinology, gastroenterology, genetics, global health, hematology, infectious diseases, neonatology, neurology, pulmonology.

Caffarelli C, Santamaria F, Bozzola E, Tchana B, Piro E, Buono E Ital J Pediatr. 2024; 50(1):244.

PMID: 39538247 PMC: 11562862. DOI: 10.1186/s13052-024-01818-3.


Cord blood granulocyte levels are associated with severe bronchiolitis in the first year of life.

Martins Costa Gomes G, Da Silva Sena C, Murphy V, Hansbro P, Starkey M, Gibson P Clin Transl Immunology. 2024; 13(9):e70004.

PMID: 39323541 PMC: 11424167. DOI: 10.1002/cti2.70004.


Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.

Mallah N, Ares-Gomez S, Pardo-Seco J, Malvar-Pintos A, Santiago-Perez M, Perez-Martinez O Hum Vaccin Immunother. 2024; 20(1):2348135.

PMID: 38738683 PMC: 11093022. DOI: 10.1080/21645515.2024.2348135.


References
1.
Berdah L, Romain A, Riviere S, Schnuriger A, Perrier M, Carbajal R . Retrospective observational study of the influence of the COVID-19 outbreak on infants' hospitalisation for acute bronchiolitis. BMJ Open. 2022; 12(10):e059626. PMC: 9627576. DOI: 10.1136/bmjopen-2021-059626. View

2.
Ledbetter J, Brannman L, Wade S, Gonzales T, Kong A . Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants. J Med Econ. 2019; 23(2):139-147. DOI: 10.1080/13696998.2019.1658592. View

3.
Baker R, Park S, Yang W, Vecchi G, Metcalf C, Grenfell B . The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020; 117(48):30547-30553. PMC: 7720203. DOI: 10.1073/pnas.2013182117. View

4.
Curatola A, Lazzareschi I, Bersani G, Covino M, Gatto A, Chiaretti A . Impact of COVID-19 outbreak in acute bronchiolitis: Lesson from a tertiary Italian Emergency Department. Pediatr Pulmonol. 2021; 56(8):2484-2488. PMC: 8242382. DOI: 10.1002/ppul.25442. View

5.
Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A . Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015; 41:97. PMC: 4681171. DOI: 10.1186/s13052-015-0203-x. View